目的 研究唑來(lái)膦酸聯(lián)合阿法骨化醇治療骨質(zhì)疏松癥的效果及其對(duì)骨轉(zhuǎn)換、骨代謝功能的影響。方法 選擇2015年1月—2017年12月在濮陽(yáng)市中原油田濮東醫(yī)院進(jìn)行診治的95例骨質(zhì)疏松癥患者，隨機(jī)分為兩組。對(duì)照組口服阿法骨化醇治療，0.5 μg/次，1次/d。觀察組聯(lián)合靜脈滴注唑來(lái)膦酸，5 mL唑來(lái)膦酸溶于100 mL生理鹽水中以恒定的速度進(jìn)行靜脈滴注。兩組均治療12個(gè)月。比較兩組的臨床治療效果，檢測(cè)兩組骨轉(zhuǎn)換指標(biāo)、骨代謝指標(biāo)，并統(tǒng)計(jì)兩組不良反應(yīng)情況。結(jié)果 觀察組的有效率為91.48%，顯著高于對(duì)照組的72.92%（P<0.05）。兩組治療后的Ⅰ型膠原交聯(lián)C-末端肽（CTX-1）均顯著降低（P<0.05），骨鈣素（OC）顯著升高（P<0.05），且觀察組較對(duì)照組變化更為顯著（P<0.05）。兩組治療后的血清堿性磷酸酶、甲狀旁腺素以及骨特異堿性磷酸酶等骨代謝指標(biāo)均顯著降低（P<0.05），且觀察組較對(duì)照組降低地更為顯著（P<0.05）。觀察組的不良反應(yīng)發(fā)生率為6.38%，與對(duì)照組的4.17%相比無(wú)明顯差異（P<0.05）。結(jié)論 唑來(lái)膦酸聯(lián)合阿法骨化醇治療骨質(zhì)疏松癥的效果明顯優(yōu)于單獨(dú)使用阿法骨化醇，可以有效改善患者的骨轉(zhuǎn)換和骨代謝狀態(tài)，具有較高的臨床參考價(jià)值。

Objective To investigate the clinical effect of zoledronic acid combined with opialaciol in the treatment of osteoporosis and its effect on bone turnover and bone metabolism.Methods Selected 95 cases of patients with opialaciol who were treated in our hospital from January 2015 to December 2016, divided into two groups randomly. The control group was treated with opialaciol, and the observation group combined zoledronic acid with intravenous drip. The clinical therapeutic effects of the two groups were compared.Results After treatment, the effective rate of the observation group was 91.48% (43/47), significantly higher than that of the control group 72.92%(35/48) (P<0.05). The CTX-1 after treatment in the two groups was significantly decreased (P<0.05), and the OC was significantly increased (P<0.05), and the observation group was more obvious (P<0.05). The serum alkaline phosphatase, parathyroid hormone and bone specific alkaline phosphatase were significantly decreased (P<0.05), and the observation group decreased more significantly (P<0.05). The incidence of adverse reactions in the observation group was 6.38% (3/47), and there was no significant difference compared with 4.17% (2/48) of the control group.Conclusion The effect of zoledronic acid combined with opialaciol on osteoporosis is significantly better than that of opialaciol alone, which can effectively improve bone turnover and bone metabolism status of patients, and has high clinical reference value.